← All Biontech SE filings

Biontech SE Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
BNTX
Biontech SE
SCHEDULE: BioNTech Major Shareholder Ownership Update
ATHOS KG, AT Impf GmbH, and Thomas Maier maintain a 40.2% beneficial ownership stake in BioNTech SE.
NASDAQ
BNTX
Biontech SE
SCHEDULE 13G/A: BioNTech SE Founders Reaffirm Substantial Ownership in Latest SEC Filing
Medine GmbH and Prof. Ugur Sahin, M.D. have jointly filed an amendment to their Schedule 13G, reaffirming their substantial beneficial ownership in BioNTech SE, with Prof. Sahin holding 17.6% and Medine GmbH holding 16.7% of the ordinary shares.